CVM · XBRL financial data

CEL-SCI financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CVM's year ends in late September)

In thousands of dollars	FY 2020Sep 30, 2020	FY 2021Sep 30, 2021	FY 2022Sep 30, 2022	FY 2023Sep 30, 2023	FY 2024Sep 30, 2024	FY 2025†Sep 30, 2025
Research and development	17,840	23,109	25,355	22,471	18,161	15,887
General and administrative	11,703	13,085	10,707	9,005	8,191	8,923
Total operating expenses	29,544	36,194	36,063	31,476	26,352	24,810
Operating income (loss)	(28,985)	(36,194)	(36,063)	(31,476)	(26,352)	(24,810)
Interest expense	1,200	—	1,081	675	746	649
Other income (expense)	39	(8)	107	(43)	178	48
Net income (loss)	(30,255)	(36,361)	(36,701)	(32,194)	(27,580)	(25,411)
Earnings per share, basic USD per share	(0.82)	(0.90)	(0.87)	—	—	—
Earnings per share, diluted USD per share	(0.82)	(0.93)	(0.87)	(0.73)	(0.51)	(6.27)
Weighted average shares, basic thousands of shares	36,759	40,662	43,149	—	—	—
Weighted average shares, diluted thousands of shares	36,759	40,694	43,149	44,480	54,045	4,056

† Share count changed about 1/9 in the period ending 2025-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (CVM's year ends in late September)

In thousands of dollars	FY 2020Sep 30, 2020	FY 2021Sep 30, 2021	FY 2022Sep 30, 2022	FY 2023Sep 30, 2023	FY 2024Sep 30, 2024	FY 2025†Sep 30, 2025
Cash and cash equivalents	15,509	36,060	22,672	4,146	4,738	10,953
Short-term investments	0	6,151	0	—	—	—
Accounts receivable	55	55	0	—	—	—
Inventory	820	2,007	2,002	2,248	1,020	—
Total current assets	17,697	45,272	25,436	6,918	6,056	11,596
Property and equipment, net	5,844	13,664	11,889	10,188	8,130	6,079
Right-of-use asset	1,199	2,056	1,884	1,698	1,496	1,275
Total assets	40,536	75,870	50,524	30,528	26,992	28,156
Accounts payable	2,023	1,676	1,618	2,010	1,448	1,061
Accrued liabilities	511	859	842	1,050	566	712
Total current liabilities	4,266	3,937	4,664	5,586	4,616	5,131
Lease liability, non-current	1,114	2,021	1,850	1,653	1,426	1,259
Total liabilities	20,810	19,336	18,360	17,313	14,125	12,199
Accumulated deficit	(381,835)	(418,196)	(454,897)	(487,091)	(514,012)	(539,423)
Total stockholders' equity	19,727	56,534	32,163	13,215	12,867	15,957
Total liabilities and equity	40,536	75,870	50,524	30,528	26,992	28,156
Common shares outstanding (cover page) thousands of shares	39,756	43,244	43,680	49,981	74,107	8,409

† Share count changed about 1/9 in the period ending 2025-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (CVM's year ends in late September)

In thousands of dollars	FY 2020Sep 30, 2020	FY 2021Sep 30, 2021	FY 2022Sep 30, 2022	FY 2023Sep 30, 2023	FY 2024Sep 30, 2024	FY 2025†Sep 30, 2025
Net income (loss)	(30,255)	(36,361)	(36,701)	(32,194)	(27,580)	(25,411)
Stock-based compensation	10,113	13,685	11,390	6,286	4,270	1,911
Depreciation and amortization	2,100	447	1,977	2,114	2,135	2,056
Net cash from operating activities	(15,276)	(18,787)	(18,241)	(22,849)	(18,811)	(17,120)
Purchases of property and equipment	(2,655)	9,016	638	362	95	38
Net cash from investing activities	(2,695)	(15,185)	5,491	(372)	(108)	(38)
Proceeds from issuing common stock	13,992	47,363	—	6,552	23,575	28,291
Proceeds from issuing equity	185	220	0	—	—	—
Net cash from financing activities	25,035	54,523	(638)	4,694	19,512	23,373

† Share count changed about 1/9 in the period ending 2025-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
CEL-SCI	6,527	not reported	(4,031)*	17.6M	1.6 quarters	Q3 FY26 10-QJun 30, 2026
Relmada Therapeutics	11,334	not reported	(9,606)*	106.7M	22.7 quarters	Q2 FY26 10-QJun 30, 2026
IGC Pharma	331	265	(1,350)*	103.4M	0.3 quarters	Q2 FY26 10-QJun 30, 2026
Cognition Therapeutics	34,012	not reported	(3,053)*	95.1M	11.1 quarters	Q2 FY26 10-QJun 30, 2026
Charlie's Holdings	527	not reported	(383)*	280.6M	1.4 quarters	Q2 FY26 10-QJun 30, 2026
Ernexa Therapeutics	5,028	not reported	(4,152)*	1.6M	1.2 quarters	Q2 FY26 10-QJun 30, 2026
Marker Therapeutics	11,331	not reported	(3,716)*	16.7M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Fibrogen	50,644	(1,474)	(3,991)*	4.0M	22.9 quarters	Q2 FY26 10-QJun 30, 2026
Armata Pharmaceuticals	23,952	not reported	(8,666)*	37.2M	2.8 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.